amylasemia/lipasemia
Explanation:
http://www.medforsk.mas.lu.se/ssrc/table1.html
Table 1
Terminology for grouping and subgrouping disease manifestations as well as their relation to signs and symptoms
Nomenclature for clinical disease manifestations
Subgroup Organ Pathoanatomic findings Pathophysiologic findings *Symptoms
Oral exocrine disease Sialoadenitis, Stomatitis sicca Hyposalivation Dyssalivation Dry mouth
Ocular exocrine disease Dacryoadenitis, Keratoconjunctivitis sicca Hypolacrimation Dyslacrimation Dry eye
Nasal exocrine disease Rhinitis sicca **Hypo-/dys- Secretion Dry nose
Surface exocrine disease Laryngotracheal exocrine disease Laryngo-tracheitis sicca **Hypo-/dys- Secretion Dry throat, Hoarse voice,
Dry cough
Pharyngooesophageal exocrine disease Pharyngitis sicca, Oesophagitis sicca **Hypo-/dys- Secretion Dry throat, Swallowing difficulties
Cutaneous exocrine disease Dermatitis sicca Hypo-/**dys- sweating, **hypo/dyssebaceous secretion Dry skin
Genitial exocrine disease Vaginitis sicca *** Dry vagina, dyspareunia
--------------------------------------------------------------------------------
Pulmonary exocrine disease Bronchitis, bronchiolitis, alveolitis, interstitial pneumonitis Obstructive ventilatory defect, reduced lung diffusion capacity Dry cough, dyspnoea
Pancreatic exocrine disease Pancreatitis Hypo-hyper- *amylasemia* Mainly sub-clinical
Internal organ exocrine disease Gastrointestinal exocrine disease (atrophic) gastritis a-/hypochlor-hydria Upper dyspepsia
Renal exocrine disease Interstitial nephritis Tubular defects Mainly sub-clinical
Hepatobiliary exocrine disease Hepatitis, (peri) cholangitis Hyperenzymaemia Mainly sub-clinical
Back to 'symptoms, diagnosis and treatment'
http://www.iac2000.org/abdetail.asp?ID=WeOrB603
XIII International AIDS Conference Abstracts
Return to Search Results
Abstract Details
[WeOrB603] The effects of hydroxyurea or placebo combined with efavirenz, didanosine, and stavudine in treatment naive and experienced patients: preliminary 24 week results from the 3d study
R. Murphy1, C. Katlama2, B. Autran3, E. Belsey4, M. Harris5, J.S.G. Montaner6, R. Pollard7, J. Hellinger8, K. Squires9, V. Calvez10, R. Gulick11, J.-P. Sommadossi12, A. Pavia13, M. Youle14, T. Schacker15, B. Berzins16, M. O'Gorman17, V. Johnson18, A. Landay19
1 Northwestern University, 303 E. Superior Street, Room 828, Chicago, Illinois, 60611, United States, 2 Groupe Hospitalier Pitie-Salpetriere, Paris, France, 3 Groupe Hospitalier Pitie-Salpetriere, Paris, France, 4 Northwestern University, Chicago, United States, 5 St. Paul's Hospital, Vancouver, Canada, 6 St. Paul's Hospital, Vancouver, Canada, 7 Galveston, United States, 8 CRI of New England, Boston, United States, 9 University of Alabama at Birmingham, Birmingham, United States, 10 Groupe Hospitalier Pitie-Salpetriere, Paris, France, 11 Cornell Clinical Trials Unit, New York City, United States, 12 University of Alabama at Birmingham, Birmingham, United States, 13 University of Utah, Salt Lake City, United States, 14 Royal Free Hospital, London, United Kingdom, 15 University of Minnesota, Minneapolis, United States, 16 Northwestern University, Chicago, United States, 17 Northwestern University, Chicago, United States, 18 University of Alabama at Birmingham, Birmingham, United States, 19 Rush University, Chicago, United States
Background: Hydroxyurea (HU) has been shown to enhance the antiviral activity of nucleosides, particularly didanosine (ddI), as well as having potential immunologic effects. The study objectives were to evaluate the 48 week effects of HU on HIV RNA, CD4 count and lymphocyte subsets in patients (pts) taking a 3 drug non-PI antiviral regimen.
Methods: 3D is an ongoing, international, multicenter, randomized, placebo-controlled 48 week trial of efavirenz (EFV) 600 mg qd + stavudine (d4T)40 mg bid + ddI 400 mg qd plus HU 600 mg bid or matching placebo (added to regimen at week 8). Eligible pts had CD4 >100 cells/uL, HIV RNA >500 c/ml, had never received HU or an NNRTI, were treatment naïve or had less than 12 weeks prior treatment with ddI and/or d4T.
Results: 100 naïve pts with median baseline (BL) HIV RNA of 46,005 c/ml and CD4 371 cells/uL and 49 treatment experienced pts with median BL HIV RNA of 6,882 c/ml and CD4 337 cells/uL were enrolled. The 24 week data, available on 91/149 pts, show that 90% of the naïve and 95% of the experienced pts had HIV RNA >500 c/ml. The mean increase in CD4 count was respectively 48 and 27 cells/uL. 42 pts reported a grade 3/4 toxicity: hyperamylasemia (9), peripheral neuropathy (7), neutropenia (6), CNS symptoms (6), hepatic transaminasemia (5), *lipasemia* (4), rash (2), pancreatitis (2), hepatitis (1); 16/42 stopped 1 or more study drugs. There were no clinical events. Immunologic and virologic studies are underway.
Conclusion: ddI/d4T/EFV + HU or placebo displays high viral efficacy with >90% pts suppressing HIV RNA to >500 c/ml at week 24. The long term effects of HU's role on proviral DNA, antiviral efficacy and immunologic function are being performed
Presenting author: R. Murphy,Northwestern University, 303 E. Superior Street, Room 828, Chicago, Illinois, 60611, United States; Telephone +1 312 908 0949; Fax +1 312 908 8281; Email [email protected]
--------------------------------------------------------------------------------
[End of Abstract Details]
Return to Search Results
Return to Top of Page
Note: I added the asterisks to heighten the relevant matters!
see above
| DR. RICHARD BAVRY (X)
PRO pts in pair: 60
|
|
